/ACRS

ACRS Stock - Aclaris Therapeutics, Inc.

Q: What is the analyst price target for ACRS?

Analyst price target information is not currently available for ACRS.

Q: What is ACRS's market cap?

Market capitalization information is not currently available for ACRS.

Healthcare|Medical - Diagnostics & Research|NASDAQ

$2.71+1.88%

+$0.05 (+1.88%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+296.7%upside

Target: $10.75

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ACRS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.43

52W High$3.48

52W Low$1.05

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$18.72M	$31.25M	$29.75M	$6.76M	$6.48M
Gross Profit	$15.93M	$13.17M	$17.79M	$2.05M	$1.35M
Gross Margin	85.1%	42.1%	59.8%	30.3%	20.8%
Operating Income	$-141,932,000	$-97,357,000	$-89,854,000	$-89,723,000	$-50,912,000
Net Income	$-132,065,000	$-88,481,000	$-86,908,000	$-90,865,000	$-51,015,000
Net Margin	-705.5%	-283.1%	-292.1%	-1344.0%	-787.0%
EPS	$-1.71	$-1.27	$-1.33	$-1.60	$-1.20

Company Overview

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Visit Website

Earnings History & Surprises

ACRS

Beat Rate

67%

Last 18 quarters

Avg Surprise

+4.1%

EPS vs Estimate

Beats / Misses

12/5

1 met exactly

Latest EPS

$-0.12

Q4 2025

EPS Surprise History

Q1 24

+18.9%

$-0.30vs$-0.37

Q2 24

+14.3%

$-0.24vs$-0.28

Q3 24

+21.1%

$-0.15vs$-0.19

Q4 24

-37.5%

$-0.11vs$-0.08

Q1 25

-11.1%

$-0.10vs$-0.09

Q2 25

+29.4%

$-0.12vs$-0.17

Q3 25

0.0%

$-0.13vs$-0.13

Q4 25

+7.7%

$-0.12vs$-0.13

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Feb 26, 2026	$-0.15	—	—	—
Q4 2025	Nov 6, 2025	$-0.13	$-0.12	+7.7%	✓ BEAT
Q3 2025	Aug 7, 2025	$-0.13	$-0.13	0.0%	= MET
Q2 2025	May 8, 2025	$-0.17	$-0.12	+29.4%	✓ BEAT
Q1 2025	Feb 27, 2025	$-0.09	$-0.10	-11.1%	✗ MISS
Q4 2024	Nov 6, 2024	$-0.08	$-0.11	-37.5%	✗ MISS
Q3 2024	Aug 7, 2024	$-0.19	$-0.15	+21.1%	✓ BEAT
Q2 2024	May 7, 2024	$-0.28	$-0.24	+14.3%	✓ BEAT
Q1 2024	Feb 27, 2024	$-0.37	$-0.30	+18.9%	✓ BEAT
Q4 2023	Nov 6, 2023	$-0.48	$-0.41	+14.6%	✓ BEAT
Q3 2023	Aug 7, 2023	$-0.45	$-0.42	+6.7%	✓ BEAT
Q2 2023	May 8, 2023	$-0.44	$-0.42	+4.5%	✓ BEAT
Q1 2023	Feb 23, 2023	$-0.46	$-0.41	+10.9%	✓ BEAT
Q4 2022	Nov 8, 2022	$-0.39	$-0.30	+23.1%	✓ BEAT
Q3 2022	Aug 3, 2022	$-0.36	$-0.31	+13.9%	✓ BEAT
Q2 2022	May 10, 2022	$-0.39	$-0.31	+20.5%	✓ BEAT
Q1 2022	Feb 24, 2022	$-0.36	$-0.37	-2.8%	✗ MISS
Q4 2021	Nov 2, 2021	$-0.27	$-0.35	-29.6%	✗ MISS
Q3 2021	Aug 5, 2021	$-0.26	$-0.34	-30.8%	✗ MISS

Frequently Asked Questions about ACRS

What is ACRS's current stock price?

Aclaris Therapeutics, Inc. (ACRS) is currently trading at $2.71 per share. The stock has moved +1.88% today.

What is the analyst price target for ACRS?

The average analyst price target for ACRS is $10.75, based on 1 analyst.

What sector is Aclaris Therapeutics, Inc. in?

Aclaris Therapeutics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.

What is ACRS's market cap?

Aclaris Therapeutics, Inc. has a market capitalization of $0.29 billion, making it a small-cap company.

Does ACRS pay dividends?

No, Aclaris Therapeutics, Inc. does not currently pay a dividend to shareholders.